HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Avapritinib Approved for GIST Subgroup.

Abstract
The FDA approved avapritinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors with mutations in exon 18 of PDGFRA-genetic alterations that render tumors insensitive to all previously approved therapies for this rare sarcoma of the digestive tract.
Authors
JournalCancer discovery (Cancer Discov) Vol. 10 Issue 3 Pg. 334 (03 2020) ISSN: 2159-8290 [Electronic] United States
PMID31974168 (Publication Type: News)
Copyright©2020 American Association for Cancer Research.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: